Lanifibranor also meets multiple key secondary endpoints including fibrosis improvement (by at least one stage without NASH worsening), insulin resistance (decreased in insulin, fasting glucose, Hb1Ac), lipid profiles (decreased in insulin, fasting glucose, Hb1Ac and triglycerides and increased in HDL), and liver injury (decreased in ALT, AST, and GGT). This evidence concerns the gene INS and Insulin resistance.